As per MRFR analysis, the South America hERGScreening Market Size was estimated at 80 (USD Million) in 2023. The South America hERG screening Market Industry is expected to grow from 89.6(USD Million) in 2024 to 287.18 (USD Million) by 2035. The South America hERG screening Market CAGR (growth rate) is expected to be around 11.17% during the forecast period (2025 - 2035).
The South America hERG Screening Market is currently characterized by a number of significant trends that are being driven by the growing demand for safer pharmaceuticals. Regulatory entities in countries such as Brazil and Argentina have prioritized comprehensive hERG screening as a component of the drug approval process in response to the increasing recognition of the significance of cardiac safety in drug development. This regulatory focus is a critical market driver, motivating biopharmaceutical companies to invest in sophisticated screening technologies to guarantee patient safety and promote compliance.Â
Additionally, the increasing incidence of cardiovascular diseases in South America is compelling pharmaceutical companies to prioritize HERG channel testing. The robust investment in healthcare infrastructure in the region is creating opportunities to enhance research and development capabilities, which can assist in the promotion of innovation in drug testing. In HERG testing, there has been a recent trend toward automation and high-throughput screening methods, which has enabled the evaluation of compound safety at a quicker and more cost-effective pace.Â
These methods are becoming more accessible to small and medium enterprises within the industry, which were previously constrained by resource constraints, thanks to regional technological advancements. Furthermore, the research capabilities of South America are being further enhanced by the increasing number of collaborations between the public and private sectors.
There is a growing opportunity to incorporate hERG screening into the development of targeted therapies as the interest in personalized medicine continues to grow. The emphasis on integrated approaches that integrate HERG testing with other cardiotoxicity assessments is also gathering traction, resulting in a comprehensive strategy for drug safety assessment.Â
In general, the South American hERG screening Market is on the cusp of a substantial transformation, which will enable the development of safer drugs and the enhancement of healthcare outcomes for the general public.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Increase in Cardiovascular Diseases
The South America hERG screening Market Industry is expected to witness significant growth due to the rising incidences of cardiovascular diseases across the region. According to the Pan American Health Organization, cardiovascular diseases account for approximately 30% of all deaths in South America, highlighting a critical health concern. As the need for precise and effective screening methods increases, organizations such as the Brazilian Society of Cardiology are actively advocating for improved diagnostic technologies.
This increased awareness and need for accurate HERG screening can drive the market upwards, as healthcare providers aim to adopt comprehensive screening solutions to enhance patient outcomes and reduce the economic burden associated with cardiovascular diseases.
Growing Pharmaceutical Research and Development Activities
The South America hERG screening Market Industry is propelled by a surge in pharmaceutical Research and Development activities focusing on drug safety and efficacy. With the rise of global pharmaceutical companies establishing research facilities in countries like Brazil and Argentina, the demand for HERG screening is on the rise. Notably, the National Agency of Sanitary Surveillance of Brazil has issued guidelines emphasizing the importance of HERG channel testing in new drug approvals, which aligns with a projected increase in new drug applications.
This strategic focus on rigorous testing has become essential for successful drug development, as it helps in identifying potential risks associated with drug compounds early in the process.
Technological Advancements in Screening Technologies
Technological advancements in screening technologies are driving the South America hERG screening Market Industry towards growth. Innovative solutions such as high-throughput screening and automated platforms are being developed, which significantly reduce the time and resources required for HERG screening. The Brazilian Institute of Science and Technology has reported an increase in the adoption of these advanced technologies in laboratories across the region, enabling accurate and efficient testing.
As regulatory bodies continue to emphasize rapid testing and the need for quality data to ensure patient safety, the demand for advanced HERG screening tools will continue to grow, thereby fueling market development.
Regulatory Support and Guidelines
Regulatory support and guidelines play a crucial role in the growth of the South America hERG screening Market Industry. Health authorities in countries such as Argentina and Colombia have begun implementing stringent regulatory frameworks that emphasize the necessity of HERG screening for new pharmaceutical products. For instance, the Argentine Drug Authority has outlined specific requirements for HERG testing in their drug approval process, compelling pharmaceutical companies to ensure their products pass this vital safety assessment.Â
The encouragement from regulatory bodies not only enforces compliance but also boosts market growth as it instills trust among end-users in the safety and efficacy of new therapies.
The South America hERG screening Market is witnessing significant growth, particularly in its Type segmentation, which includes Gene KCNH2 and Mutant KCNH2. The Gene KCNH2 segment is crucial as it deals with the genetic factors influencing cardiac repolarization and ion channel functionality, essential for understanding various cardiac disorders. As awareness of genetic implications in health increases, this segment plays an important role in the development of tailored therapeutic approaches. Mutant KCNH2, on the other hand, signifies variants in the KCNH2 gene that can lead to arrhythmias and other cardiac problems.
The prominence of this segment stems from the growing need for accurate diagnostic tools to identify at-risk populations. With an increasing focus on precision medicine and personalized care in South America, innovations in HERG screening are becoming invaluable for healthcare providers and pharmaceutical companies alike. Furthermore, the regulatory environment is gradually evolving to adapt to these emerging technologies, fostering opportunities for growth and development in this segment. The ongoing research and significant investments in genetic testing and HERG screening technologies enhance the efficacy of treatment options and improve patient outcomes.
Overall, the emphasis on genetic components in the HERG screening Market aligns well with the regional health priorities, making the Type segmentation a vital aspect in the medical landscape of South America.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The Ion Channel segment within the South America hERG screening Market plays a crucial role in understanding cardiac safety and drug development. This segment is primarily divided into voltage-gated and ligand-gated channels, each contributing distinctly to pharmaceutical research. Voltage-gated channels are essential in regulating neuronal and muscle excitability, making them significant for drugs targeting conditions such as epilepsy and cardiac arrhythmias. Similarly, ligand-gated channels are vital for synaptic transmission and play a critical role in neurotransmission.
The growth of the healthcare sector in South America, fueled by advancements in Research and Development and increased investment in biotechnology, enhances the importance of these Ion Channel screening methods. Moreover, the rising demand for efficient drug screening techniques drives the development of innovative platforms that leverage these channel types, reflecting the increasing focus on patient safety and regulatory compliance in the region. Overall, this segment is positioned to contribute significantly to the evolving landscape of drug discovery in South America.
The South America HERG screening Market, focusing on the Application segment, showcases significant growth driven by various therapeutic areas. Within this landscape, the Antiarrhythmic application plays a crucial role in ensuring safe drug development due to its impact on cardiac safety assessments, reflecting the increasing demand for effective treatment of arrhythmias. The Antipsychotic category is also noteworthy, as it addresses mental health challenges prevalent in the region, emphasizing the need for robust screening methods to mitigate adverse cardiac effects commonly associated with psychiatric medications.
Antibiotics represent another vital aspect of HERG screening, underscoring the importance of evaluating cardiac safety as antibiotic use continues to evolve, especially in combating resistant strains. Other applications within the market contribute to a diversified approach to drug safety, catering to emerging therapeutic areas and technological advancements in drug development. The South America hERG screening Market is thus witnessing a blend of traditional and innovative applications, highlighting the importance of comprehensive safety evaluations to align with regional healthcare demands.
The South America hERG screening Market is experiencing significant growth, driven by the need for advanced pharmacological safety assessments in the region. Brazil, as a major player, holds a significant share in the market and is pivotal due to its large pharmaceutical industry, increasing investments in Research and Development, and an expanding healthcare sector. Mexico also plays a crucial role, benefiting from its strategic location and improvements in healthcare infrastructures that enhance drug screening processes. Argentina, while smaller, demonstrates growth potential in HERG screening due to rising awareness of drug safety and regulatory compliance.
The Rest of South America, although less dominant, is gradually emerging as a developing hub for HERG screening technologies, influenced by growing demand for safer therapeutic drugs and increased adoption of innovative healthcare solutions. The region is witnessing trends such as collaboration between public and private sectors aimed at improving drug safety, further propelling the growth of the South America hERG screening Market through enhanced technological capabilities and regulatory frameworks.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
South America hERGScreening Market Key Players and Competitive Insights:
The South America hERG screening Market is witnessing notable expansion, driven by the increasing prevalence of cardiac-related disorders and a growing need for effective drug safety testing. The competition within this market is characterized by a mix of established players and emerging companies, all vying to capture market share as awareness of the HERG channel's significance in pharmaceuticals continues to rise. The demand for efficient HERG screening technologies has also increased, given the stringent regulatory environments and the emphasis on patient safety. This landscape is constantly evolving, presenting both opportunities and challenges for market participants. Innovations in technology and research capabilities are essential for firms to maintain a competitive edge in this growing market.
Abbott Laboratories stands out in the South American HERG screening Market, showcasing substantial strengths that fortify its competitive positioning. The company has a significant market presence bolstered by its commitment to research and development, which enables Abbott Laboratories to offer advanced screening technologies and robust testing solutions tailored for the unique demands of the South American healthcare landscape. Their established reputation for quality and reliability further enhances their attractiveness to pharmaceutical companies seeking comprehensive screening methodologies. Abbott's effective collaborations with local research institutions and healthcare organizations have also contributed to their strong foothold in the region, enabling them to identify market opportunities and develop tailored service offerings that cater to specific regional needs.
Pfizer remains a key player in the South America HERG screening Market, leveraging a robust portfolio of products and services that focus on enhancing drug safety and efficacy. The company’s commitment to innovation facilitates the development of groundbreaking HERG screening technologies that meet regulatory standards while addressing the local market's specific requirements. Pfizer's strengths lie not only in its comprehensive testing services but also in its strategic alliances and partnerships within the region, which enhance its market reach and operational capabilities.Â
The company's active participation in mergers and acquisitions further positions it advantageously in the competitive landscape, as these strategic moves allow for the integration of advanced technologies and expansion of its service offerings. Overall, Pfizer maintains a strong influence in South America by consistently evolving to meet the challenges posed by the dynamic healthcare environment in the region.
Key Companies in the South America hERGScreening Market Include:
South America hERGScreening Market Developments
Recent developments in the South America hERG screening Market indicate a growing emphasis on safety pharmacology as drug manufacturers in the region focus on compliance with international regulations. Notably, Abbott Laboratories and Pfizer are involved in enhancing their respective HERG screening processes to ensure cardiovascular safety for new drug candidates. In July 2023, Roche announced a partnership with a local biotechnology firm to improve drug testing capabilities. Thermo Fisher Scientific has expanded its service offerings in Brazil to cater to the rising demand for HERG screening services. Financial growth is evident, with market valuations for companies like Celerion and Fujifilm experiencing a notable increase due to investments in innovative screening technologies.Â
In terms of mergers and acquisitions, AstraZeneca's acquisition of a small biotech firm in June 2023 has strengthened its research capabilities in pharmacology within the South American market. Major happenings in recent years include Sanofi's establishment of a new research center in Argentina in August 2022, focusing on drug safety evaluations, underlining the importance placed on HERG screening within the regulatory framework of the region. The ongoing developments cater to an evolving landscape where drug safety is becoming increasingly prioritized in South America.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 80.0(USD Million) |
| MARKET SIZE 2024 | 89.6(USD Million) |
| MARKET SIZE 2035 | 287.18(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.17% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Abbott Laboratories, Pfizer, Viva Biotech, Roche, Thermo Fisher Scientific, Celerion, Fujifilm, AstraZeneca, Merck & Co, Bristol Myers Squibb, Sanofi, Novartis |
| SEGMENTS COVERED | Type, Ion Channel, Application, Regional |
| KEY MARKET OPPORTUNITIES | Growing drug development initiatives, Increased focus on cardiac safety, Adoption of advanced screening technologies, Collaborations with local research institutions, Expansion of regulatory frameworks |
| KEY MARKET DYNAMICS | Increasing cardiac safety regulations, Growing drug development investments, Rising prevalence of cardiac diseases, Advancements in screening technologies, Demand for cost-effective solutions |
| COUNTRIES COVERED | Brazil, Mexico, Argentina, Rest of South America |
Frequently Asked Questions (FAQ) :
The South America HERG Screening Market is projected to be valued at 89.6 million USD in 2024.
By 2035, the market is anticipated to reach a value of 287.18 million USD.
The market is expected to grow at a CAGR of 11.17% from 2025 to 2035.
Brazil is expected to dominate the market with values of 30.0 million USD in 2024 and 95.0 million USD in 2035.
The Gene KCNH2 segment of the market is valued at 35.0 million USD in 2024.
The Mutant KCNH2 segment is projected to be valued at 174.55 million USD by 2035.
The market in Mexico is expected to reach a value of 80.0 million USD by 2035.
In 2024, the HERG Screening Market in Argentina is expected to be valued at 20.0 million USD.
Major players include Abbott Laboratories, Pfizer, Roche, and Merck & Co among others.
The Rest of South America segment is anticipated to reach a value of 47.18 million USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
